RECRUITINGPhase 1 / Phase 2INTERVENTIONAL
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
About This Trial
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Who May Be Eligible (Plain English)
Who May Qualify:
- Fully understand the study and voluntarily sign the willing to sign a consent form form.
- Male or female 18-70 years of age.
- Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
- Eastern Cooperative Oncology Group (ECOG) 0 to 1.
- Life expectancy \> 3 months.
Who Should NOT Join This Trial:
- The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-70 years of age.
* Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
* Eastern Cooperative Oncology Group (ECOG) 0 to 1.
* Life expectancy \> 3 months.
Exclusion Criteria:
* The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.
Treatments Being Tested
DRUG
ZG006
ZG006 will be administered as an intravenous (IV) infusion.
DRUG
ZG005
ZG005 will be administered as an intravenous (IV) infusion.
Locations (1)
Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China